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Abstract  
This report provides a non-technical introduction to practical methods for using cost-effectiveness 
analysis to address health equity concerns, with applications to low-, middle- and high-income 
countries.  These methods can provide information about the likely impacts of alternative health 
policy decisions on inequalities in health, financial risk protection and other health-related outcomes 
that may be considered unfair, allowing for the distribution of costs as well as benefits.  They can 
also provide information about the trade-offs that sometimes arise between improving total health 
and reducing health inequalities of different kinds.  We distinguish three general ways of using cost-
effectiveness analysis to address health equity concerns: (1) equity impact analysis, which quantifies 
the distribution of costs and effects across a population by equity-relevant variables such as 
socioeconomic status, ethnicity, location, gender, age and severity of illness; (2) equity constraint 
analysis, which counts the cost of choosing fairer but less cost-effective options; and (3) equity 
weighting analysis, which uses equity weights or parameters to explore how much concern for 
equity is required to choose fairer but less cost-effective options.  We hope this report will raise 
awareness of the practical tools of cost-effectiveness analysis that are now available to help give 
health care and public health policy makers a better understanding of who gains and who loses from 
their priority setting decisions. 
 
Further resources are available at this website:  
http://www.york.ac.uk/che/research/equity/economic_evaluation/ 
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Executive summary 
Introduction 
Health equity has risen to prominence on policy agendas across the world, in the wake of the 
universal health coverage movement and landmark international reports on social inequalities in 
health and health care.  Conventional cost-effectiveness analysis (CEA) can help decision makers 
identify smarter investments that deliver larger health gains from limited resources.  Currently, 
however, most CEA studies do not provide information about who gains and who loses from policy 
decisions.  Both producers and users of cost-effectiveness analysis need to start paying more 
attention to health equity concerns  W and this report shows how. 
 
Cost-effectiveness analysis 
In the health sector, CEA usually focuses on getting the largest total health benefit for a given cost. 
Standard CEA of this kind can help to inform decision making in at least four different health policy 
contexts, each of which involves different though overlapping communities of decision makers, 
analysts and stakeholders: 
 
1. Purchasing costly new health care technologies  W e.g. whether to fund imatinib for 
stomach cancer, at what price, and for which patients? 
2. Designing health care benefit packages  W e.g. whether to cover diabetes in a public 
health insurance plan, and if so which diabetes treatments to include? 
3. Investing in health care infrastructure  W e.g. whether to invest in a community health 
worker programme, and if so how to prioritise investments in different geographical 
areas? 
4. Public health  W e.g. whether to implement a sugar tax, and if so how much should it be? 
 
CEA provides decision makers with a standard way of assessing value for money.  It compares the 
value of the outcomes generated by a policy intervention against those that could have been 
achieved with alternative uses of the same resources, i.e. the  Ropportunity costs ?.  In (1), for 
example, the funding could be used for other hospital-based cancer treatments  W or, with more 
difficulty, shifted towards primary care.  In (2), there may only be enough income from premiums or 
taxes to cover diabetes or dementia  W but not both.  In (3), the investment could instead be used to 
buy hospital equipment.  Lastly, in (4), a sugar tax will increase the price of sugar-sweetened 
products, potentially requiring households to cut back on consumption.  In each case, equity may 
play an important but typically unanalysed role: standard CEA does not tell us who gains the most, 
nor who bears the heaviest burden of opportunity costs. 
 
Trade-offs between maximising total health and reducing health inequities 
In  Rwin-win ? cases standard CEA may be all that is needed, because the cost-effective policy that 
maximises total health also reduces a particular health inequity.  However, more careful analysis of 
equity impacts may be needed in  Rwin-lose ? cases, when a policy improves total health but harms 
health equity, and in  Rlose-win ? cases, when improvement in equity comes at the expense of lower 
total health. 
 
Improving total health and health equity are often aligned, and  Rwin-win ? cases are common.  When 
delivered equally to all social groups, for example, programmes of vaccination and primary care for 
infectious diseases may be not only highly cost-effective but also more beneficial to disadvantaged 
groups at higher risk of infection. But delivery is not always equal.  For example, delivery costs may 
be relatively high and effective healthcare coverage relatively low in poor urban areas and remote 
rural areas which lack well-resourced clinics and struggle to recruit qualified medical staff.  In such 
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cases, delivery may be unequal unless additional resources are invested to facilitate delivery to 
disadvantaged groups  W resulting in trade-offs between cost-effectiveness and health equity, and 
hard choices between more equal delivery versus larger total health gains. 
 
Three ways of using cost-effectiveness analysis to address health equity concerns 
(1) Equity impact analysis. The effects of alternative policy options can be broken down by 
one or more social variables. The distribution of opportunity costs may also be 
presented, based on evidence and assumptions about where the funding comes from 
and who would otherwise have gained the most from alternative use of scarce 
resources. 
(2) Equity constraint analysis.  Equity can be analysed as an ethical constraint on the 
pursuit of cost-effectiveness, rather than as an outcome.  The opportunity cost of 
imposing this ethical constraint can be calculated as the difference in total health 
benefit between the policy that offers the most total health and a more equitable policy 
option. 
(3) Equity weighting analysis. When there are trade-offs between improving total health 
and reducing health inequity, the implications of different value judgements about 
those trade-offs can be analysed by conducting sensitivity analysis around how much 
decision makers care about reducing health inequity.  This can be done using  Requity 
weights ? for health benefits to people with different characteristics, or  Requity 
parameters ? quantifying the degree of concern for reducing health inequity versus 
improving total health. 
 
Alongside these analyses, one can also conduct an equity evidence review to provide useful 
information for decision makers by identifying previous studies on the relevant health inequities and 
the distributional impacts of similar policies that have been studied in other contexts. 
 
Two specific methods of equity-informative cost-effectiveness analysis 
We describe two specific methods of equity-informative CEA.  Extended Cost-Effectiveness Analysis 
(ECEA), developed by the Disease Control Priorities, 3rd edition (DCP3) project (www.dcp-3.org), 
examines the social distribution of costs, health effects and financial risk protection effects. 
Distributional Cost-Effectiveness Analysis (DCEA), developed by the University of York, examines the 
distribution of health benefits and opportunity costs and then, if health equity trade-offs are 
identified, conducts equity constraint and weighting analyses to provide further information about 
the nature of those trade-offs.  ECEA is particularly useful when health policy decisions have 
substantial impacts on household financial risk protection, as is often the case in low- and middle-
income countries.  DCEA, by contrast, is better suited to cases where impacts on household income 
and financial risk protection are less important, as is the case in high-income countries like the UK 
with well-developed social protection safety nets and universal publicly funded health care systems. 
 
Key messages for decision makers who use cost-effectiveness studies 
x Some decisions involve trade-offs between improving health and reducing health 
inequity. 
x Such trade-offs can occur, for example, when delivering services to disadvantaged 
communities requires additional cost, due to poor infrastructure or utilisation barriers. 
x In such cases, equity-informative CEA can help make fairer decisions. 
 
 
 
 
Fairer decisions, better health for all:health equity and cost-effectiveness analysis  v 
 
Key messages for analysts who produce cost-effectiveness studies 
x Who gains most depends on social variation in several factors including health risks, 
access to care, adherence to care, quality of care, clinical effects, and capacity to 
benefit. 
x Providing a full picture of health equity impacts requires analysing not only who gains 
but also who bears the opportunity costs of diverting scarce resources from other uses. 
x Understanding health equity impacts can benefit from analysis of social inequality in 
service delivery and the implementation costs of attempting to reduce this inequality. 
x Health equity findings should include sensitivity analysis that helps decision makers 
understand the implications of alternative value judgements about equity. 
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Introduction 
Health equity has risen to prominence on policy agendas, in the wake of the universal health 
coverage movement (Gwatkin and Ergo 2011, Norheim, Ottersen et al. 2014, Cotlear, Nagpal et al. 
2015, Wagstaff, Cotlear et al. 2016) and landmark international reports on inequality in health 
(Marmot, Friel et al. 2008, Marmot, Allen et al. 2012) and health care (WHO 2014, World Health 
Organization 2015). However, the cost-effectiveness studies that are routinely used across the globe 
to inform decision making in health care and public health rarely provide information about who 
gains and who loses from alternative decisions (Sassi, Archard et al. 2001, Cookson, Drummond et al. 
2009, Culyer 2012, Johri and Norheim 2012, Daniels, Porteny et al. 2016). 
 
Equally, most studies of health equity lack a cost-effectiveness perspective.  A cost-effectiveness 
perspective can enhance health equity research in two important ways.  First, as well as 
understanding the nature and causes of health inequalities, decision makers need to know how the 
policy options open to them are likely to impact upon health inequalities.  This requires not only 
epidemiological analysis of the determinants of health inequalities, but also economic analysis of 
costs and how policies are likely to change individual and organisational behaviour.  Second, when 
evaluating the health equity impacts of policies the distribution of opportunity costs matters as well 
as the distribution of benefits.  If costs fall on government budgets for health, education or other 
public services, for example, this is likely to have a disproportionate impact on disadvantaged 
populations who rely most heavily on those public services. 
 
This report brings together two different strands of literature  W on cost-effectiveness analysis and on 
health equity  W and shows how they can be integrated in a practical way to provide decision makers 
with useful information about health equity concerns.  It describes methods for using cost-
effectiveness analysis to provide new information about inequalities in health-related outcomes that 
may be considered unfair, or as  Rhealth inequities ?. 
 
In recent years there have been a number of methodological advances in this area which have been 
developed into practical tools  (Verguet, Murphy et al. 2013, Asaria, Griffin et al. 2015, Verguet, 
Laxminarayan et al. 2015, Verguet, Kim et al. 2016).  The technical details of these new methods 
have been published in scientific journals in a form suitable for health economists, but may require 
further description to be communicated in a more user-friendly manner suitable for the policy 
makers and managers who commission and use cost-effectiveness evidence and for students and 
scholars in disciplines outside health economics. 
 
This report focuses on methods of analysis, rather than processes of decision making.  Evidence 
about health inequities generated using the methods described in this report is only one input into 
decision making, and there are further important issues  W not addressed in this report  W about how 
to design processes of decision making that appropriately reflect concerns about health inequities 
(Culyer and Lomas 2006).  Re-aligning the methods of CEA to address equity concerns is only one 
facet of the much larger question of how to design fair processes of decision making that 
appropriately address equity concerns (Culyer 2012, Culyer 2016). Equity-informative CEA can only 
address an important subset of the diverse stakeholder concerns about fairness that may arise in 
relation to a specific decision, and decision makers will always need to consider wider issues and 
wider sources of information.  One useful approach to ensuring that decision makers give due 
attention to wider equity concerns, for example, is the use of  Requity checklists ?(Culyer and 
Bombard 2012, Norheim, Baltussen et al. 2014).  More fundamentally, robust institutional 
structures, processes and incentives are needed to ensure that decision makers take appropriate 
steps to reduce inequities in health, as well as new methods of analysis.  Analysis of the health 
equity implications of decisions cannot help to improve decision making, for example, if it is poorly 
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conducted or communicated, if it is based upon the idiosyncratic value judgements of a narrow 
group of experts rather than a broader community of stakeholders, if policy advisers lack sufficient 
training to understand the findings, or if the conclusions are disregarded by decision makers who 
merely pay lip-service to health equity concerns. 
 
Implicitly or explicitly, all CEA studies already embody social value judgements about equity in 
scoping and methodological decisions about the relevant policy options and comparators, about 
which costs and effects to measure, about how to compare costs and effects of different kinds, 
about how to aggregate costs and effects for different people and organisations, about how to value 
future costs and effects, and so on (Shah, Cookson et al. 2013).  To take just one example, a 
methodological decision to include  Rproductivity costs ? in the cost denominator will increase the 
implicit priority given to life-extending treatments for  Rproductive ? citizens, such as high-earning 
parents of young children, compared with  Runproductive ? citizens, such as frail older people.  Indeed, 
the basic ethical underpinning of standard cost-effectiveness analysis adheres to an equity principle 
 W the principle that health policy makers should seek to increase sum total population health as 
much as possible given scarce resources, and hence that each unit of health gain should be valued 
equally, regardless of who obtains it (Cookson 2015).  These value judgements are rarely mentioned 
in applied CEA studies or health technology assessment (HTA) reports, but are extensively discussed 
in textbooks, methods guidance documents and other underpinning literature (Culyer 2016).  This 
article shows how to go beyond embodying pre-specified value judgements about equity within 
applied CEA studies, and towards using the techniques of CEA to provide new information about the 
health equity implications of alternative policy options that facilitate deliberation among decision 
makers and stakeholders (Culyer 2012, Culyer 2016). 
 
This report has two main sections.  In the first section, we introduce key concepts of cost-
effectiveness analysis and health equity.  In the second section we then describe three general 
approaches and two specific methods for using cost-effectiveness analysis to address health equity 
concerns.  These approaches are illustrated with applications to low-, middle- and high-income 
country settings. 
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Part I: Concepts 
Cost-effectiveness analysis 
Cost-effectiveness analysis compares the costs and effects of one policy option with another policy 
option  W which might be  Rdo nothing ? (Drummond, Sculpher et al. 2015).  Health effects are often 
measured using a composite summary index of health, such as the quality-adjusted life year (QALY) 
or the disability-adjusted life year (DALY), to facilitate comparison between policies in different 
disease areas with diverse and distinct mortality and morbidity impacts.  This allows the calculation 
of a cost per QALY gained, or cost per DALY averted.  A cost-increasing policy option can then be 
considered  Rcost-effective ? if its cost per unit of health gain compares favourably with alternative 
ways of using scarce resources. 
 
In a public health system with a fixed budget, the displaced activities will comprise alternative health 
programs that would have produced alternative health benefits.  Cost-effectiveness can then be 
defined as a test of whether a program will improve total health.  A cost-effective policy will have a 
positive net health impact, because its health gains will outweigh the health losses from shifting 
expenditure away from other health programs.  By contrast, a cost-ineffective policy will have a 
negative net health impact, because the health losses from shifting expenditure away from other 
health programs will outweigh the health gains.  The policy objective underpinning conventional CEA 
can then be interpreted as the quasi-utilitarian health equity objective of maximising sum total 
health in the general population (Culyer 2006, Cookson 2015).  CEA can thus help decision makers to 
choose investments that increase total health, and avoid investments that reduce total health.  This 
interpretation of opportunity costs in terms of forgone health benefits is more problematic if there is 
no fixed health budget, in which case opportunity costs may instead fall on household consumption 
(via increased taxes or insurance premiums) or on reductions in public expenditure on programs not 
primarily designed to improve health.  Whatever the setting in which CEA is used, however, the 
recognition of opportunity costs  W i.e. that resources used in the provision of a program would have 
generated value if used elsewhere  W is fundamental to CEA.  Every benefit attributed to a program 
must be weighed against those displaced when resources are diverted from alternative activities. 
 
To provide useful information for priority setting decisions, it is important to give a clear description 
of the options being compared and the policy context.  Decision makers can then assess how far 
these options are relevant to their own decision making context.  Comparisons of hypothetical policy 
options may have limited use in helping with the task of setting priorities between specific health 
sector investment decisions.  However, they can help with the task of  Ragenda setting ? or  Rmaking the 
case ? in favour of investment in a broad policy area (e.g. mental health) or a broad objective or 
direction of travel for policy making.  For example, a 2013 report by the Lancet Commission on 
Investing in Health made the case that low- and middle- income countries should all set a long-term 
policy ambition of achieving universal health coverage by the year 2035 (Jamison, Summers et al. 
2013).  This case was supported by an economic evaluation comparing two hypothetical policy 
options  W no growth in health spending versus sustained long-term growth so as to achieve universal 
health coverage by 2035.   
 
Cost-effectiveness studies of specific policy alternatives can help to inform priority setting in at least 
four decision contexts, each of which involves different though overlapping communities of decision 
makers, analysts and stakeholders.  Decisions that are considered investments should also consider 
disinvestments as these are likely to have distributional consequences as well: 
 
1. Pricing and reimbursement of new pharmaceuticals and other health technologies  W e.g. 
whether to fund imatinib for stomach cancer, at what price, and for which patients? 
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2. Health care benefit package design  W e.g. whether to cover diabetes in the national 
health insurance plan, and if so which diabetes interventions to include in the package? 
3. Investments in healthcare organisation and delivery infrastructure  W e.g. whether to 
invest in a community health worker programme, and if so how many and what kinds of 
new staff to recruit, located where, and with what pay and conditions? 
4. Public health investments and regulations  W e.g. whether to implement a sugar tax, and 
if so how much should it be? 
 
In each case, cost-effectiveness analysis can provide decision makers with a standard way of 
assessing the value for money of specific policy options compared with alternative uses of scarce 
resources.  In (1), for example, the funding for imatinib could be used for other hospital-based 
cancer treatments  W or, with more difficulty, shifted towards primary care.  In (2), there may only be 
enough money to cover diabetes or dementia  W but not both.  In (3), the investment could instead 
be used to buy hospital equipment.  And in (4), the opportunity costs of a sugar tax will be felt by 
consumers paying higher food prices  W potentially pushing some further into poverty.  In each case, 
equity plays an important but typically unanalysed role: standard cost-effectiveness analysis does 
not tell us who gains most, nor who bears the heaviest opportunity costs. 
 
Health equity 
In this report, we use the term  Rhealth inequities ? in a broad sense to refer to differences in health-
related outcomes that may be considered unfair, inequitable or unjust (Whitehead 1992, Norheim, 
Baltussen et al. 2014).  Health equity then refers to the policy goal of seeking to reduce or eliminate 
health inequities.  Under our broad definition, health inequities may include not only inequalities in 
health per se but also inequalities in outcomes related to ill-health and lack of access to affordable 
health care, such as catastrophic health care expenditure, impoverishment, inability to work, and 
inability to perform domestic tasks such as child care.  These outcomes may be unequally distributed 
 W for example, decisions about public funding for a particular medical technology could have 
differential impacts by social group on healthcare costs, or on ability to work or perform domestic 
tasks, and the resulting financial risks to households. 
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Figure 1 ƐŚŽǁƐĚŝĨĨĞƌĞŶĐĞƐŝŶƉĞŽƉůĞ ?ƐůŝĨĞƚŝŵĞĞǆƉĞƌŝĞŶĐĞŽĨŚĞĂůƚŚŝŶŶŐůĂŶĚĂŶĚƚŚŝŽƉŝĂŝŶƚŚĞ
year 2011 (Dawkins 2015, Asaria et al. 2015, Love-Koh. 2015); see Annex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Distribution of Healthy Life Expectancy in England and Ethiopia in 2011 
Note: This figure compares quintile groups of healthy life expectancy at birth as predicted by socioeconomic status and sex 
only. 
 
The figure shows healthy life expectancy at birth by health quintile groups.  The health quintile 
groups are based on healthy life expectancy at birth as predicted by just two equity-relevant 
variables: socioeconomic status and sex.  We use health quintile groups, rather than socioeconomic 
groups, to emphasise that policy makers may be concerned with many different sources of 
inequality in health.  In principle, we could also include variation due to further equity-relevant 
variables such as ethnicity, region, working conditions and so on.  The figure shows that there is a 
gradient in health within each country, but also that there is an inequality between countries since 
the most advantaged health group in Ethiopia does not achieve as much health as the least 
advantaged in England.  If considered unfair, the differences in Figure 1 represent health inequities. 
 
Differences in health-related outcomes are sometimes considered fair, and equality in health-related 
outcomes are sometimes considered unfair.  For example, providing different health services to 
people with different needs may be fair, and providing the same services to people with different 
ŶĞĞĚƐŵĂǇďĞƵŶĨĂŝƌ ?DŽƌĞĐŽŶƚƌŽǀĞƌƐŝĂůůǇ ?ŝĨƐŽŵĞŽŶĞ ?ƐůŝĨĞŝƐĐƵƚƐŚŽƌƚďǇĂƌĂŶĚŽŵĂĐĐŝĚĞŶƚ W a 
matter of  Rresidual ? or  Runexplained ? bad luck, not avoidable or remediable by any social action  W this 
might by some be considered unfortunate or tragic, but not a matter of social injustice (Hausman 
2013).  This can make a big difference to inequality analysis.  For example, if we consider 
 Runexplained ? variation to be unfair, we would need to include it in Figure 1 and predict the  Rex post ? 
distribution of healthy length of life, allowing for unexplained variation in mortality and morbidity, 
which would include much more variation than the  Rex ante ? distribution of healthy life expectancy 
(Asada, Hurley et al. 2015). 
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In assessing how far a particular difference is  Runfair ?, there are always thorny issues of both 
scientific and social value judgement to consider.  For example, inequality in life expectancy may be 
considered more  Runfair ? when it is caused by unequal childhood circumstances than by lifestyle 
choices in adulthood.  Judgements of this kind turn on contestable scientific judgements about 
complex causal pathways in the face of imperfect evidence, as well as contestable ethical issues of 
social value judgement.  That is why we use the cautious phrase  Rdifferences that may be considered 
unfair ? in our definition of inequity, rather than the bolder phrase  Runfair differences ?  W to emphasise 
that value judgements about equity are properly a matter for decision makers and stakeholders 
rather than analysts. 
 
We also use the less well-known term,  Rhealth equity impacts ?, to mean changes in health inequities 
brought about by policy interventions.  In practice, due to data limitations, modelling of health 
equity impacts is typically restricted to differences associated with categorical social group variables 
such as income or wealth groups, education groups, ethnic groups, by gender or region.  For 
example, a social variable commonly used in low- and middle-income country applications is wealth 
quintile based on a survey of household assets, and a social variable commonly used in high income 
country applications is socioeconomic quintile group based on small area deprivation.  These were 
the socioeconomic variables used to estimate the figures in Figure 1 for Ethiopia and England, 
respectively.  When suitable data are available, health equity impacts can also include impacts on 
within-group differences associated with continuous social variables, such as income, or even 
impacts on the whole-population univariate distribution of health unrelated to any particular social 
variable. 
 
There are many reasons for policy concern about health inequalities, one of which is that all forms of 
social inequality  W including health inequality  W may act as a kind of  Rsocial pollution ? that is bad for 
ĞǀĞƌǇŽŶĞ ?ƐŚĞĂůƚŚŝŶƐŽĐŝĞƚǇ ?tŝůŬŝŶson and Pickett 2010).  In principle, if a particular decision had 
large impacts on the distribution of wealth and power within society, it might be worth 
incorporating the resulting change in the level of  Rsocial pollution ? into cost-effectiveness analysis.  
When evaluating most health policies, however, it is reasonable to assume that impacts on social 
inequality as a whole will be relatively small and hence that any indirect impacts on health via 
changes in the level of  Rsocial pollution ? will be too small to be worth including in the analysis. 
 
The tools described in this report can be used to provide information about health equity impacts for 
decision makers and stakeholders; it is then up to them to process the information, draw 
conclusions and take decisions based on their own value judgements. 
 
Accounting for the social distribution of opportunity costs  
The distribution of policy costs matters, as well as the distribution of policy benefits.  Understanding 
health equity impacts requires analysing not only who gains health benefits but also who bears the 
opportunity costs  W the forgone health benefits that could have been generated through alternative 
ways of using the same scarce resources may also be unequally distributed.  The distribution of 
opportunity costs will depend crucially on where the funding for the policy or programme comes 
from.  For example, if the money comes from an increase in progressive general taxation, the 
absolute opportunity costs are likely to be borne disproportionately by the rich and the opportunity 
costs in terms of losses in health and wellbeing may be equally distributed.  By contrast, if it is 
funded by reducing public expenditure on other health, education or welfare services, the 
opportunity costs in terms of losses in health and wellbeing may be borne disproportionately by 
poorer individuals who rely more heavily upon public services.  The same applies to foreign aid 
funding that would otherwise be used to fund alternative programs that disproportionately benefit 
more socially disadvantaged people. 
 
Fairer decisions, better health for all:health equity and cost-effectiveness analysis  7 
 
In order to estimate net health equity impact accurately one needs to compare the health benefits 
and health opportunity costs using the same metric.  To do this, it is usually necessary to measure 
health outcomes using a generic health measure that can be compared across different diseases, 
such as QALYs or DALYs, rather than in disease specific units such as cases of malaria prevented.  
This is because we typically do not know which patient groups will bear the health opportunity costs, 
and without a generic measure of health it is hard to compare the value of a case of malaria 
prevented versus a case of cancer or tuberculosis or heart disease.  The only case in which it might 
make sense to compute health benefits and opportunity costs in the same disease specific unit is if 
there is a ĨŝǆĞĚďƵĚŐĞƚĨŽƌĂ Rvertical programme ? in a particular disease area, which cannot be used 
for treating any other disease.  In that case, the opportunity costs of alternative uses of the budget 
will all fall on patients with that specific disease, and so it may make sense to measure both health 
benefits and opportunity costs in disease specific units.  Where reliable data on morbidity impacts 
are not available for computing QALYs or DALYs, an alternative is to measure health benefits in 
terms of life years or mortality risk reduction.  However, this is less comparable with health 
opportunity costs because some interventions focus primarily on reducing morbidity rather than 
mortality, and the balance between the two can vary substantially between different disease areas. 
 
Insofar as public and donor expenditure tends disproportionately to benefit socially disadvantaged 
groups, this provides a tough benchmark for assessing the health equity impacts of specific public or 
donor-funded programmes compared with other uses of public or donor funding.  As Figure 2 
shows, interventions that may initially seem to have a  Rpro-poor ? health equity impact may in fact be 
equity-neutral or even  Ranti-poor ?, when one considers where the money is coming from and what 
the alternative uses of that money would be.  This is shown with the downward arrows that convert 
the  Rgross ? health impacts  W considering programme benefits only  W to  Rnet ? health impact, after 
allowing for the health opportunity costs of alternative uses of the money.  
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Case 1: Equal Opportunity Costs 
 
 
 
Case 2: Unequal Opportunity Costs (Larger for the Poor) 
 
 
Figure 2. Distribution of Net Health Benefits from a Hypothetical Programme 
 
The top panel of Figure 2 illustrates the assumption that health opportunity costs (forgone health 
benefits) are constant across all groups.  For an investment in a hypothetical programme the gross 
health benefits as seen in the top lines of each case in Figure 2, show the same distribution of 
benefit.  In case 1, as the opportunity costs are accounted for by taking the forgone benefits to be 
constant across wealth quintiles leads one to conclude there is a  Rpro-poor ? distribution of net health 
benefits.  That is, the poor appear to benefit more in the net benefits of case 1 with negative net 
health benefits for the richest.  The bottom panel illustrates the assumption that the opportunity 
costs are unequally distributed and disproportionately borne by more socially disadvantaged groups.  
The result is now a  Rpro-rich ? distribution of net health benefits, with negative net health benefits for 
the poorest.  This public programme is less pro-poor than alternative public programmes.  So if the 
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goal is to reduce health inequality, the money would be better spent on other public programmes 
rather than this one. 
 
Empirically estimating the distribution of opportunity costs is difficult.  However, work is under way 
by researchers at the University of York to estimate the social distribution of the opportunity costs of 
public healthcare expenditure in England, and similar studies in the future could provide other 
relevant estimates to be incorporated in future work. 
 
Trade-offs between total health and health equity 
Health maximisation and health equity are often aligned, but not always.  The  Rhealth equity impact 
plane ? in Figure 3 helps one to think about the potential trade-offs (McAuley, Denny et al. 2016). The 
vertical axis shows the cost-effectiveness of a health intervention.  As explained above, this can 
under certain assumptions be interpreted as its  Rnet total health impact ?  W i.e. the total health 
benefits of the programme minus the forgone health benefits that would have been obtained by 
spending the money on other health programmes.  The horizontal axis shows the  Rnet health equity 
impact ?, which refers to the net impact upon fairness in the distribution of health after allowing for 
opportunity costs as well as benefits.  Health equity impact can be defined and measured in various 
ways, as discussed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Health Equity Impact Plane 
 
The plane defines four quadrants.  In quadrant I ( Rwin-win ?), the policy improves both total health 
and equity, and in quadrant III ( Rlose-lose ?), the policy harms both.  In these two cases, health 
maximisation and equity are aligned.  In the other two quadrants, by contrast, health maximisation 
and equity are opposed and there may be trade-offs.  In quadrant II ( Rwin-lose ?), the policy is good 
for total health but bad for equity, and in quadrant IV ( Rlose-win ?), the policy is bad for total health 
but good for equity. 
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If all policies fell in the two aligned quadrants (win-win and lose-lose) then there would be no need 
to analyse health equity impacts.  We would then have a guarantee that a policy identified as cost-
effective using standard CEA approaches would always improve health equity, and a cost-ineffective 
policy would always harm health equity. 
 
Many policies do indeed fall into these two quadrants.  In low-income countries, for example, 
investments in high-cost hospital treatments often fall into the  Rlose-lose ? quadrant of being neither 
cost-effective nor likely to reduce health inequality, insofar as they deliver relatively small health 
gains per unit of cost and disproportionately benefit wealthy urban elites.  By contrast, programmes 
of vaccination and primary care for infectious diseases often fall into the  Rwin-win ? quadrant of 
delivering large health gains per unit cost and reducing health inequality, insofar as they 
disproportionately benefit socially disadvantaged groups at high risk of infection. 
 
However, socially disadvantaged groups may sometimes gain less than more advantaged groups 
from a decision to fund a particular medical technology, due to unequal access, utilisation, 
adherence, quality and outcomes of healthcare (Tugwell, de Savigny et al. 2006).  For example, 
access costs may be relatively high, and effective healthcare coverage relatively low, in urban slums 
and remote rural areas which lack well-resourced clinics and struggle to recruit qualified medical 
staff.  In such cases, there may be trade-offs between health maximisation and health equity  W and 
hard choices between more equal delivery versus larger total health gains. 
 
Measuring health equity impacts  
Health inequities can be measured in different ways depending on the decision problem in hand and 
the equity concerns of the relevant decision makers and stakeholders.  There are many useful 
training resources describing how to do so, in general (O'Donnell, van Doorslaer et al. 2008, 
Fleurbaey and Schokkaert 2011, Asada, Hurley et al. 2014), in the context of health system 
performance monitoring (World Health Organization 2013) and in the context of cost-effectiveness 
analysis (Asaria, Griffin et al. 2013).  In each case, at least four basic questions must be addressed: 
 
1. Equality of what? 
2. Equality between whom? 
3. Equality indexed how?  
4. Equality adjusted how? 
 
In relation to  Requality of what? ?, for example, the central equity concern might be inequality in 
health, or inequality in capacity to benefit, or inequality in financial risk protection; and there are 
many different metrics for measuring each of these concepts.  In relation to  Requality between 
whom? ?, for example, the unit of analysis might be individuals or households or geographical areas 
or social groups, and the inequality breakdowns of interest may relate to socioeconomic status, 
ethnicity, gender or other social variables.  In relation to  Requality indexed how? ?, different indices of 
inequality may contain different normative judgments and can yield quite different patterns of 
change depending for example whether they are defined in terms of relative or absolute differences 
and in terms of achievement or shortfall (e.g. survival or mortality) (Harper, King et al. 2010) (Arcaya, 
Arcaya et al. 2015, Kjellsson, Gerdtham et al. 2015, Wagstaff 2015).  In relation to  Requality adjusted 
how ?, it is rarely enough to measure crude, unadjusted differences in health-related outcomes: one 
should also consider adjusting for factors that influence the assessment of how far differences are 
unfair (Asada, Hurley et al. 2014, Asada, Hurley et al. 2015). For example, differences in health care 
utilisation may be fair if they are due to difference in needs or preferences; and differences in health 
outcomes may be fair if they are due to differences in exogenous factors beyond the control of 
ŚĞĂůƚŚƐĞƌǀŝĐĞƐ ?ƐƵĐŚĂƐĂƉĂƚŝĞŶƚ ?ƐĂŐĞ ?dŚŝƐĂĚũƵƐƚŵĞŶƚƉƌŽĐĞƐƐĐĂŶǇŝĞůĚĚŝĨĨĞƌĞŶƚĂŶƐǁĞƌƐ
depending on the selection of standardising variables, the choice of reference values for those 
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variables, and different model specifications and methods of adjustment (e.g. direct versus indirect 
standardisation).  To measure health inequality that is considered unfair, for example, differences in 
mortality risk between socioeconomic groups may be partly driven by (or masked by) differences in 
the age structure of the different groups.  Insofar as age is not considered to be an  Runfair ? 
determinant of mortality, an adjustment is needed to control for the influence of age on mortality.  
There are various more or less sophisticated ways of adjusting for  Rfair ? differences in outcomes, but 
whatever approach is taken it is important to be as clear and explicit as possible about the 
contestable value judgements about fairness that underlie such adjustments. 
  
Health equity concerns can be placed on a spectrum from general to specific. At the broad end of 
this spectrum is concern to reduce unfair inequality in lifetime health between all individuals 
(Norheim 2010, Robberstad and Norheim 2011). At the specific end of the spectrum might be 
concern for equalising the benefits of a particular policy between urban and rural groups over a 
particular time period.   There are at least four aspects of health equity concern that can vary 
depending on whether a more general or specific perspective is adopted: 
 
1. Levels vs. gains  W concern for equality in health levels (more general) rather than 
concern for the health gains arising from a specific policy (more specific) 
2. Outcome specificity  W concern for equality in health (more general) rather than concern 
for equality in the ill-health burden of cancer (more specific)  
3. Time horizon  W concern for equality over the life course (more general) rather than 
equality in a particular age group or over a specific time period (more specific) 
4. Single vs. multiple social variables  W concern for inequality by multiple social variables 
(more general) rather than by one social variable (e.g. urban vs. rural) 
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Figure 4 illustrates a specific equity impact, using a modified version of a hypothetical example used 
in a 2004 article in the Lancet (Gwatkin, Bhuiya et al. 2004). It shows two policies for increasing 
coverage of skilled birth attendance in a low-income country  W a  Runiversal ? policy and a  Rtargeted ? 
policy that focuses on developing maternity service infrastructure in socially disadvantaged areas.  It 
shows that the  Rtargeted ? policy is less equal in terms of the distribution of gains: it delivers larger 
benefits to socially disadvantaged groups, in terms of increases in the proportion of birth deliveries 
attended by a skilled midwife.  From this highly specific perspective, the  Rtargeted ? policy may seem 
unfair to people in the middle and upper wealth groups who gain less. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Coverage gains by wealth group, comparing standard and targeted options for improving maternity 
services in a low income country  W hypothetical example based on (Gwatkin, Bhuiya et al. 2004) 
 
However, Figure 5 shows that the  Rtargeted ? policy is more equal in terms of the resulting levels of 
attended deliveries.  If one takes this broader perspective, the  Rtargeted ? policy may seem fairer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Coverage levels by wealth group, comparing standard and targeted options for improving 
maternity services in a low-income country  W hypothetical example 
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One might also wish to take an even broader perspective, by looking at impacts on inequalities in 
lifetime health of the kind illustrated by Figure 1 earlier in this report.  From this perspective, the 
 Rtargeted ? policy will seem even fairer, since it will help to reduce the large pre-existing inequality in 
lifetime health between socioeconomic groups.  This is easy to show using mathematical indices of 
inequality.  However, an important challenge for communicating lifetime health impacts to decision 
makers is that individual policy decisions typically have small impacts on expected lifetime outcomes 
for the average citizen.  Health equity impacts still matter, however, even though they seem small 
from the  Rex ante ? perspective of expected changes in risk of future mortality and morbidity  W since 
ǁĞĂƌĞƐƚŝůůƚĂůŬŝŶŐĂďŽƵƚůĂƌŐĞĂŶĚŝŵƉŽƌƚĂŶƚĐŚĂŶŐĞƐŝŶŵĂŶǇƉĞŽƉůĞ ?ƐůŝǀĞƐĨƌŽŵĂŶ Rex post ? 
perspective looking back at how far they experienced a long and healthy life (Eyal, Hurst et al. 2013).  
From an  Rex ante ? population perspective, the cost-effectiveness impacts of most policy decisions 
also seem small  W costing little to the average citizen and adding only a small proportion to average 
healthy life expectancy.  Furthermore, a sustained sequence of small impacts can over time 
accumulate into a large impact. 
 
Quantifying health equity trade-offs 
When there are trade-offs between health equity and total health  W i.e. we know that the policy lies 
in either the  Rwin-lose ? or  Rlose-win ? quadrants of Figure 3  W it can be helpful to provide a more 
refined quantitative analysis of those trade-offs.  One general approach, which we call  Requity 
constraint analysis ?, is to count the cost of choosing a fairer but less cost-effective policy, in terms of 
a reduced total health (QALY equality) benefit.  Another general approach, which we call  Requity 
weighting analysis ?, is to quantify how much concern for health inequity is required to recommend a 
fairer but less cost-effective policy option, using sensitivity analysis.  This sensitivity analysis can be 
done by specifying alternative  Requity weights ? for health benefits to different people, or alternative 
values of an  Rinequality aversion parameter ? quantifying your degree of concern for reducing health 
inequality versus improving total health (Norheim 2013) (Asaria, Griffin et al. 2013, Wagstaff, Cotlear 
et al. 2016).  Sensitivity analysis can help decision makers understand the implications of alternative 
value judgements.  The aim of health equity trade-off analysis is thus to help inform a decision 
making process, rather than to impose a particular set of value judgements upon decision makers. 
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Part II: Methods 
This part of the report describes three general ways of using cost-effectiveness analysis to evaluate 
policy concerns about health equity, each of which addresses different equity questions (Cookson, 
Drummond et al. 2009, Johri and Norheim 2012).  These are: equity impact analysis, equity 
constraint analysis and equity trade-off analysis.  Table 1 provides a definition of each approach and 
the questions they help to answer. 
 
Table 1. Three General Approaches to Evaluating Health Equity Concerns 
Approach Description Questions Answered 
1. Equity impact 
analysis 
Disaggregation of the relevant 
costs and benefits by equity-
relevant sub-groups, providing 
a dashboard of results.  
How much do different social groups gain or lose?  
This may be in terms of money, health services, health 
outcomes or other outcomes related to ill-health and 
access to affordable health services, such as financial 
risk protection. 
2. Equity constraint 
analysis 
Calculation of the health 
opportunity cost of choosing a 
fairer option rather than a 
more cost-effective option. 
How much total health benefit is forgone if a more 
cost-effective option is ruled out on equity grounds? 
3. Equity weighting  
analysis 
Sensitivity analysis around the 
value of health equity impacts, 
based on different concepts of 
inequality, and the strength of 
concern for reducing health 
inequality. 
How large is the health equity impact in terms of 
standard summary metrics of inequality?  How much 
concern for health equity is required to choose a more 
equitable option compared with a more cost-effective 
option? 
 
We use the umbrella term  Requity-informative cost-effectiveness analysis ? to describe any study that 
uses the methods of cost-effectiveness analysis to provides information about health equity 
objectives other than improving total health.  We illustrate two specific methods of equity-
informative cost-effectiveness analysis.  Extended Cost-Effectiveness Analysis (ECEA), developed by 
the Disease Control Priorities, 3rd edition project (www.dcp-3.org), examines the social distribution 
of costs, health effects and financial risk protection effects. Distributional Cost-Effectiveness Analysis 
(DCEA), developed by the University of York, examines the distribution of health benefits and 
opportunity costs and then, if health equity trade-offs are identified, conducts equity constraint and 
equity trade-off analyses to provide further information about the nature of those trade-offs.  The 
key difference between these two methods is that ECEA presents estimation of financial risk 
protection (e.g. poverty reduction benefits) and disaggregated information on a range of different 
costs and effects, while DCEA aggregates and compares all costs and effects using the common 
currency of QALYs or DALYs, thus allowing the construction of summary indices of inequaity and 
equity weighting analysis. 
 
We first describe methods of equity evidence review that can be performed alongside or prior to 
cost-effectiveness analysis in order to provide information about health equity concerns.  
 
Equity evidence review 
Equity evidence review can address a range of health equity questions of interest to decision 
makers, for example  RWhat are the relevant health equity issues? ?,  RWhat do stakeholders think? ?, 
 RWhat is already known about the size of pre-existing health inequities? ? and  RWhat do studies of 
past policies suggest may be the potential health equity impacts of the policy options currently 
under consideration? ?.   
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There are published guidelines for using the methods of systematic review of randomised controlled 
trials to gather information about equity impacts, such as the PROGRESS framework adopted by 
both the Campbell and Cochrane Collaborations (O'Neill, Tabish et al. 2014).  Box 1 describes a 
Cochrane systematic review regarding food supplementation for disadvantaged young children; 
another example is the review by Brown and colleagues of the equity impact of interventions and 
policies to reduce smoking in youth (Brown, Platt et al. 2014) and another is the review by Noor and 
colleagues about reducing inequity in use of insecticide-treated bed nets in Kenya (Noor, Amin et al. 
2007).  Systematic review methods have an important role in helping to avoid the all-too-common 
trap of falling unknowingly into a selective reading of the evidence, and to avoid  Rre-inventing the 
wheel ?.  However, systematic reviews can be resource intensive, and often require several months of 
work by large multi-disciplinary teams.  Furthermore, there are ongoing debates about appropriate 
review methods for complex interventions where theoretical and observational evidence may play a 
more central role than randomised controlled trials.  So if the requisite capacity is not available to 
conduct a systematic review, it may be useful to undertake a rapid review.   
 
It is also possible to conduct a review of philosophical arguments about equity in relation to a 
particular case, such as the  Rethical case review ? approach that Miljeteig and colleagues used to 
examine end-of-life decisions in a neonatal unit in India (Miljeteig, Johansson et al. 2010).  However, 
in conducting a review of this kind analysts must be wary of going too far down the road of 
adjudicating between alternative views of justice in an attempt to answer the question  Rwhat is 
fair? ?, rather than clarifying alternative points of view so that decision makers can make up their own 
minds. 
 
 
  Box 1  W Example of an equity evidence review 
Food supplementation for disadvantaged young children  W a systematic review 
Kristjansson and colleagues use the Cochrane systematic review method to examine 
interventions to address malnutrition in young children. They primarily review the effectiveness 
of supplementary feeding interventions, but they secondarily look at how such interventions 
interact with inequalities, implementation and adverse outcomes. We focus in this synopsis on 
what they find for inequality. 
The authors develop a conceptual framework to guide thinking about how inequalities may 
factor into childhood nutrition and health. Equity was then evaluated by looking at outcomes 
for given subgroups such as age, sex, level of malnourishment (baseline health) and 
socioeconomic status.  
Meta-analysis of the studies and differences between sub-groups were then conducted. The 
results of this review and analysis find that supplementary feeding programmes have unequal 
impacts on certain subgroups, being more effective for children who were poorer and more 
malnourished, but no difference of impact in other subgroups such as by sex of the child.  
Reference: Kristjansson E, Francis DK, Liberato S, Benkhalti Jandu M, Welch V, Batal M,  
 1   Example of an equity evidenc  review 
 
 supplementation for disadvant ged young children  W a systematic review 
 
Kristjansson and colleagues use the Cochrane systematic review method to examine interventions to 
address mal utrition in young child en.  They primarily review t  effectiveness of supplementary 
feeding interventions, but they secondarily look at how such interventions interact with inequalities, 
implementation and adverse outcomes.  We focus in this synopsis on what they find for inequality. 
 
The authors develop a conceptual framework to guide thinking about how inequalities may factor into 
childhood nutrition and health.  Equity was then evaluated by looking at outcomes for given subgroups 
such as age, sex, level of malnourishment (baseline health) and socioeconomic status.  
 
Meta-analysis of the studies and differences between sub-groups were then conducted.  The results of 
this review and analysi  find that supplementary feeding programmes have unequal impacts on certain 
subgroups, being more effective for children who were poorer and more malnourished, but no difference 
of impact in other subgroups such as by sex of the child.  
 
Reference: Kristjansson E, Francis DK, Liberato S, Benkhalti Jandu M, Welch V, Batal M, Greenhalgh T, 
Rader T, Noonan E, Shea B, Janzen L, Wells GA, Petticrew M. Food supplementation for improving the 
physical and psychosocial health of socio-economically disadvantaged children aged three months to five 
years. Cochrane Database of Systematic Reviews 2015, Issue. DOI: 10.1002/14651858.CD009924.pub2. 
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Equity impact analysis 
Equity impact analysis examines who gains and who loses from one policy option compared with 
another, and by how much.  Typically, this approach yields a  Rdashboard ? of outcomes, showing gains 
and losses by social group for various different kinds of costs and effects.  This provides the decision-
maker with relevant disaggregated information on the equity impacts.  
 
An example of equity impact analysis alongside cost-effectiveness analysis in a high income context 
is the study by Holmes and colleagues of the impacts of minimum alcohol pricing in the UK (Holmes, 
Meng et al. 2014).  This study estimated the social class distribution of effects on alcohol 
consumption, spending and alcohol-related health harm, and found that benefits are substantially 
concentrated on heavy drinkers in routine and manual worker households. 
 
The DCP3 project has developed a specific method of cost-effectiveness analysis that incorporates 
equity impact analysis and analysis of financial risk protection effects as well as health effects, called 
 Rextended cost-effectiveness analysis ? (ECEA) (Verguet, Laxminarayan et al. 2015). This method has 
now been applied to about 20 studies of policy interventions in several different low- and middle-
income country settings, producing breakdowns of costs, health benefits and financial risk 
protection benefits by socioeconomic quintile group (Verguet and Jamison forthcoming).  Box 2 
gives an example of ECEA relating to tobacco taxes in China.   
 
Sometimes equity impact analysis only examines the benefits of a policy, not the costs.  As explained 
above, this provides an incomplete picture of health equity impact, since it only looks at one side of 
the distributional coin: the costs may also be unequally distributed. 
 
Equity impact analyses can also be performed outside the context of cost-effectiveness analysis, to 
look at the impacts of changes in risk factors, health behaviours or the utilisation of effective health 
technologies, rather than the impacts of specific policy options.  For example, Bajekal and colleagues 
examined the impacts on coronary heart mortality in England from 2000 to 2007 of changes in risk 
factors and treatment utilisation in different social groups (Bajekal, Scholes et al. 2012).  This kind of 
study does not directly inform the priority setting task of selecting between specific future policies, 
as it does not provide information about either the costs of those policies or their effects on risk 
factors, health behaviours or the utilisation of effective health technologies.  However, it can provide 
decision makers with useful contextual information for policy making purposes, in raising awareness 
of the importance of particular factors and their contributions to health inequality.  
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Box 2  W Example of an equity impact analysis 
Tobacco tax in China  W ĂŶ ?ĞǆƚĞŶĚĞĚĐŽƐƚ-ĞĨĨĞĐƚŝǀĞŶĞƐƐĂŶĂůǇƐŝƐ ? ? ? 
This modelling exercise examines a 50% excise tax on cigarettes over a 50-year period.  In aggregate, this is 
estimated to save 231 million life years, add $703 billion in tax revenue to government budgets, reduce 
expenditure on tobacco-related illness and improve financial risk protection.  
The ECEA further breaks down model inputs by equity-relevant groups, in this case by five income quintiles.  The 
descriptive tables of the paper show how input variables such as smoking prevalence, cigarette consumption, 
price elasticity and health utilization are all parametrized according to income quintile.  
The results are presented in a dashboard-like format, where the aggregate results are broken down into results 
for each quintile group.  For example, the years of life gained are more concentrated on the poor (79 million in 
the poorest quintile) than the rich (11 million in the richest quintile), as seen in the figure below. Expenditures 
on tobacco, which one may worry would be regressive with a new excise tax, also show a progressive 
distribution in absolute terms, or an inverted U distribution in relative terms. In either case, the tax is shown not 
to overly harm the poor. 
 
Lastly, the ECEA also incorporates financial risk protection benefits. In the case of the Chinese tobacco tax, this is 
measured as a money-metric value of insurance. This is similarly disaggregated by income quintile, showing that 
there is more financial risk protection for the poorer quintiles.  
Reference: Verguet S, Gauvreau CL, Mishra S, MacLennan M, Murphy SM, Brouwer ED, Nugent RA, Zhao K, Jha 
P, Jamison DT. The consequences of tobacco tax on household health and finances in rich and poor smokers in 
China: an extended cost-effectiveness analysis. The Lancet Global Health. 2015 Apr 30;3(4):e206-16. 
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Finally, a form of equity impact analysis known as  Rbenefit incidence analysis ? looks at the benefits of 
public healthcare spending as a whole for different social groups.  Traditionally, this kind of analysis 
has typically assumed that health benefits are proportional to health care consumption, and has only 
looked at the average benefits of the current overall level of spending rather than the marginal 
benefits of changes in spending.  So traditional forms of benefit incidence analysis have not been 
useful for predicting the health benefits of a policy decision to change expenditure from the current 
baseline level.  However, some benefit incidence analyses are now starting to look at marginal 
benefits, by exploiting data on sub-national variation and change in expenditure and outcomes, and 
so can be more useful for priority setting purposes (Kruse, Pradhan et al. 2012). 
 
Equity constraint analysis 
Equity can be analysed as a constraint on the pursuit of cost-effectiveness, rather than as a goal or 
outcome to be pursued in its own right. The health opportunity cost of imposing this ethical 
constraint can be calculated as the difference in total health benefit between the most cost-effective 
policy option and a more equitable policy option.  The health loss associated with choosing a more 
equitable option thus gives an indication of the value the decision maker places on equity (Williams 
and Cookson 2006).  This approach can be implemented either using a simple cost-effectiveness 
framework comparing two or more options given a fixed budget, or using more specialised 
 Rmathematical programming ? techniques to handle complex choices involving different amounts of 
expenditure on different programmes (Earnshaw, Richter et al. 2002, Epstein, Chalabi et al. 2007). 
  
Box 3  W Example of an equity constraint analysis 
HIV Treatment in South Africa  W a mathematical programming study 
Cleary and colleague analyse the equity concern to provide only the most effective treatment as a 
constraint on improving total health in relation to anti-retroviral (ART) HIV treatment in South Africa. 
They measure cost-effectiveness in terms of QALYs gained per unit of cost, and equity in terms of the 
percentage of met need for ART. 
The study uses mathematical programming to examine different treatment delivery scenarios under 
different health budgets.  As budgets increase, more total health can be provided.  However, at given 
budget levels there are trade-offs and more cost-effective solutions exist that deliver larger total health 
gains by offering some people cheaper but less effective treatments rather than fully meeting their needs 
by proving the most effective treatment.   Hence particular target levels of met need (the equity 
constraint) are only achievable by sacrificing total health. 
This approach highlights that the opportunity cost of equity can be understood in terms of the amount of 
health that is forgone by implementing a more equitable solution, as opposed to implementing the most 
cost-effective solution under a given budget constraint. 
Reference: Cleary, S., Mooney, G., & McIntyre, D. (2010). Equity and efficiency in HIV-treatment in South 
Africa: the contribution of mathematical programming to priority setting. Health Economics, 19(10), 
1166-1180. doi:10.1002/hec.1542 
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Equity weighting analysis 
The final approach is health equity weighting analysis.  In contrast to the previous approaches, this 
approach attempts to quantify the overall health equity impact, using summary indices of inequality, 
and to analyse trade-offs between the health equity impact and the net health impact (Johansson 
and Norheim 2011, Norheim 2013, Asaria, Griffin et al. 2015).  The basic idea is to conduct sensitivity 
analysis in order to find out how much you need to care about reducing inequality to recommend a 
fairer option rather than a health maximising option.  This sensitivity analysis can be done by 
specifying alternative  Requity weights ? for health benefits to different people, or alternative values of 
an  Requity parameter ? quantifying your degree of concern for health equity versus improving total 
health.  Box 4 illustrates, using an example comparing more equitable and more cost-effective ways 
of increasing uptake of colorectal cancer screening in England. 
 
Many different characteristics of health policies and the people affected by them could be used as 
the basis for setting  Requity weights ?, and several different equity weighting systems have been 
proposed (Wailoo, Tsuchiya et al. 2009, Cookson, Griffin et al. 2014). Many of these systems do not 
pay special attention to the social characteristics of people, but rather focus on their health 
characteristics  W for example, their current severity of illness, or their overall lifetime experience of 
health including past, present and future health (Nord 1993, Williams 1997, Lindemark, Norheim et 
al. 2014, Ottersen, Mæstad et al. 2014, Ottersen, Forde et al. 2016, Rowen, Brazier et al. 2016).  
These systems tend to be based upon one or more  Requity parameters ?, such as an inequality 
aversion parameter within a social welfare function, which specifies how much you care about 
reducing unfair health inequality rather than how much you care about individuals with certain 
social characteristics (Asaria, Griffin et al. 2013).  An  Requity parameter ? then indirectly implies a set 
of equity weights for people with different characteristics, in conjunction with information about the 
existing distribution of health between individuals with different characteristics.  These implied 
weights will then change in response to changes in the distribution of health and social variables. 
 
If decision makers are interested in impacts on relative inequality (e.g. life expectancy ratios), as well 
as absolute inequality (e.g. life expectancy gaps) then they will require an estimate of the baseline 
distribution of health  W since the impact on relative inequality depends upon the baseline.  
Furthermore, since equity trade-off analysis requires the estimation of net health impacts, benefits 
have to be quantified using the same metric as opportunity costs, for example using annual 
mortality risk, life years, QALYs or DALYs. 
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  Box 4  W Example of an equity weighting analysis 
Bowel Cancer Screening in England  W Ă ?ĚŝƐƚƌŝďƵƚŝŽŶĂůĐŽƐƚ-effectiveness ĂŶĂůǇƐŝƐ ? ? ? 
This study compares two strategies for increasing uptake of a universal bowel cancer screening programme.  
dŚĞ “ƚĂƌŐĞƚĞĚ ?ƐƚƌĂƚĞŐǇĨŽĐƵƐĞƐŽŶƐŽĐŝĂůŐƌŽƵƉƐǁŝƚŚůŽǁƵƉƚĂŬĞ ?ďǇƐĞŶĚŝŶŐĂƉĞƌƐŽŶĂůŝƐĞĚƌĞŵŝŶĚĞƌĨƌŽŵ
ƚŚĞŝƌĨĂŵŝůǇĚŽĐƚŽƌ ?ƚŚĞ “ƵŶŝǀĞƌƐĂů ?ƐƚƌĂƚĞŐǇƐĞŶĚƐĂŐĞŶƌŝĐƌĞŵŝŶĚĞƌƚŽĞǀĞƌǇŽŶĞ ?/ŶĞƋƵĂůŝƚǇŝŵƉĂĐƚƐĂƌĞ
analysed by deprivation, ethnicity and gender, and then combined to assess the overall impact.  The 
illustrations below focus on inequality by deprivation.  The left hand panel below shows unequal health by 
deprivation group before the screening programme.  The right hand panel shows unequal uptake of 
ƐĐƌĞĞŶŝŶŐĨƌŽŵƚŚĞ “ƐƚĂŶĚĂƌĚ ?ƉƌŽŐƌĂŵŵĞĂŶĚĂĨƚĞƌƚŚĞ “ƚĂƌŐĞƚĞĚ ?ĂŶĚ “ƵŶŝǀĞƌƐĂů ?ƌĞŵŝŶĚĞƌƐƚƌĂƚĞŐŝĞƐ ? 
  
Unequal health: Quality Adjusted Life Expectancy 
at birth by deprivation group 
Unequal screening uptake before and after the 
two reminder strategies 
 
The left hand panel below shows the resulting changes in health.  The targeted strategy is inequality 
reducing but produces less total health than the universal strategy, which is inequality increasing.  Which 
strategy you consider best depends on how much you care about reducing health inequality versus 
improving total health.  The right hand panel shows how this trade off can be quantified using the 
inequality aversion parameter from an Atkinson social welfare function.  Which strategy you consider better 
depends on how much you care about reducing health inequality  W ŝŶƚŚŝƐĐĂƐĞ ?ƚŚĞ “ƚĂƌŐĞƚĞĚ ?ƐƚƌĂƚĞŐǇŝƐ
better if your inequality aversion parameter is greater than 8.  Recent survey data suggest the average 
member of the English general public has an inequality aversion parameter of around 11 (Robson, Asaria et 
al. 2016). 
 
  
Change in health due to reminders How the best strategy depends on the inequality 
aversion parameter 
 
Reference Asaria, Miqdad, Susan Griffin, and Richard Cookson. "Distributional Cost-Effectiveness Analysis: A 
Tutorial." Medical Decision Making 36.1 (2016): 8-19. 
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In the past, some authors have taken a sceptical view about the value of equity weighting analysis 
(Sassi, Archard et al. 2001). However, we take a more pragmatic approach.  Equity weighting analysis 
will not be useful when there are no trade-offs between improving total health and health equity.  
However, equity trade-off analysis may be useful when decision makers do face difficult trade-offs.  
Often there will not be trade-offs, as seen in many examples where there are  Rwin-win ? scenarios.  
However, previous studies have often not paid close attention to the question of whether additional 
delivery costs are required in disadvantaged communities due to poor infrastructure, weak 
governance and access barriers; nor have they analysed the distribution of opportunity costs from 
public or donor budgets.  Due to issues of this kind, there will sometimes be difficult trade-offs due 
to social variation in access, adherence and effectiveness, and social variation in opportunity costs, 
and in such cases there may be a need for equity trade-off analysis (Eyal, Hurst et al. 2013).  Analysis 
of these trade-offs can help decision makers understand the implications of alternative value 
judgements; and the use of equity parameters and weights can help form useful  Rbenchmarks ? for 
decision makers to compare across different decisions.  As with the cost-effectiveness threshold, this 
kind of benchmark can be useful to decision makers as a way of justifying their decisions in the face 
of competing political demands from rival stakeholders, and of facilitating both transparency and 
consistency between decisions. 
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Conclusion 
In response to growing policy concern about health equity, the tools of economic evaluation are 
being re-fashioned to provide useful evidence about health equity impacts and trade-offs.  Our 
report has described the key concepts and methods now available for using cost-effectiveness 
analysis to analyse health equity concerns.  We have distinguished three general approaches: (1) 
equity impact analysis, (2) equity constraint analysis and (3) equity weighting analysis.  We have also 
described two specific methods of  Rdistributional economic evaluation ? that incorporate equity 
impact analysis within economic evaluation:  Rextended cost-effectiveness analysis ? (ECEA) and 
 Rdistributional cost-effectiveness analysis ? (DCEA).  ECEA examines the distribution of costs, health 
outcomes and financial risk protection outcomes; and DCEA combines equity impact analysis with 
equity constraint and trade-off analyses. 
 
Our report has the following conclusions for decision makers who use cost-effectiveness studies: 
 
x Some decisions involve equity trade-offs between total health and health equity. 
x Equity trade-offs can occur when delivering services to more disadvantaged 
communities if it requires additional investment of resources, due to poor 
infrastructure, weak governance, and utilisation barriers. 
x In the face of equity trade-offs, equity-informative economic evaluation can be used to 
provide useful quantitative information to help make fairer decisions and improve 
health for all. 
 
Our report also has the following conclusions for analysts who produce cost-effectiveness studies: 
 
x Who gains most depends on social variation in several factors including health risks, 
access to care, adherence to care, quality of care, clinical effects, and capacity to 
benefit. 
x Providing a full picture of health equity impacts requires analysing not only who gains 
but also who bears the opportunity costs of diverting scarce resources from other uses. 
x Accurate estimates of health equity impacts requires analysis of social inequality in 
service delivery and the implementation costs of attempting to reduce this inequality, 
rather than merely assuming that services will be delivered and used in the same way 
and at the same cost in advantaged and disadvantaged communities 
x Health equity findings should include sensitivity analysis that helps decision makers 
understand the implications of alternative value judgements about equity. 
 
Using CEA to analyse distributional equity impacts and trade-offs requires the same basic analytical 
skills as standard cost-effectiveness analysis.  However, it is more demanding in terms of data 
requirements because it requires social distributions of key parameters rather than merely 
population average values. Data limitations can be particularly severe in low-income countries which 
lack basic health information systems such as vital statistics on births and deaths, and hospital and 
primary care administrative data. However, as the DCP3 project has amply demonstrated, 
distributional economic evaluation studies can successfully be performed in low-income countries 
using existing datasets and existing, large survey-based datasets in low-income countries such as 
hE/& ?ƐDƵůƚŝƉůĞ/ŶĚŝĐĂƚŽƌůƵƐƚĞƌ^ƵƌǀĞǇ ?D/^ ?ĂŶĚ /&/ŶƚĞƌŶĂƚŝŽŶĂů ?ƐĞŵŽŐƌĂƉŚŝĐĂŶĚ,ĞĂůƚŚ
Surveys (DHS), among others, which include information disaggregated by socioeconomic status 
(ICF-International-USAID 2016, UNICEF 2016).  Datasets are improving all the time, and in the future 
it will become increasingly feasible to estimate social distributions of key parameters in economic 
evaluation studies. 
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Three important frontiers of research in this field are (1) research on the distribution of opportunity 
costs of funding health programmes from different sources (e.g. public health care, donor budgets, 
taxation), (2) research on the implementation costs of achieving more equal delivery and utilisation 
of services in disadvantaged communities, and (3) research on public and stakeholder views about 
health equity trade-offs to provide benchmark values to help guide decision makers faced with 
difficult policy trade-offs.  Work on the distribution of opportunity costs issue is ongoing in England, 
drawing on existing research on variation in health care expenditure and outcomes at sub-national 
level (Claxton, Martin et al. 2013).  This issue is particularly challenging in low- and middle-income 
countries where the existence of informal health systems, donor aid, and a variety of health 
financing models creates challenges for identifying where the opportunity costs lie, and is a critical 
area for further research. 
 
We hope this report will help those who produce, commission and use evidence to support priority 
setting in health care and public health to navigate the practical options for using the techniques of 
cost-effectivenes analysis to provide policy makers with more useful information about the health 
equity implications of their decisions. 
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Annex: Computation of the distribution of healthy life expectancy in Ethiopia 
In England, the baseline socioeconomic distribution of healthy life expectancy can be estimated by 
linking whole-population administrative data on mortality, population and small area deprivation, 
and making adjustments for self-reported health-related quality of life based on survey data from a 
nationally representative random sample (Asaria et al., 2015, Love-Koh et al., 2015).  However, 
estimating the distribution of healthy life expectancy is more challenging in low income countries 
such as Ethiopia, which lack reliable census and vital registration systems that can provide whole-
population data on all-age population and mortality.  We developed an approach which draws on 
WHO data on healthy life expectancy, a previous analysis of Demographic Health Surveillance (DHS) 
survey data on child mortality by household wealth asset group, and further adjustments for the 
distribution of morbidity based on additional DHS data on child and adult disease prevalence. 
 
Our approach involved a three stage process.  First, we took the average HALE values for men and 
women from the WHO database (WHO, 2015). Second, relative mortality weights by socioeconomic 
group were applied, based on a previous analysis of modelled life expectancy drawing on DHS data 
on child mortality by household asset group. Third, relative morbidity weights by socioeconomic 
group were applied based on available prevalence data. This is explained more fully below and in 
Annex Table 1.  Like many methods used in practice in the global health field, our approach involves 
making a number of assumptions in order to extract useful information from imperfect data.  It 
nevertheless provides a starting point for analysis until better data becomes available. 
 
Stage 1: Healthy Life Expectancy 
Healthy life expectancy (HALE) is a summary measure of population health measured in healthy life 
years (HALYs) that has begun to be included in WHO datasets of life expectancy.  It is developed 
ƵƐŝŶŐ^ƵůůŝǀĂŶ ?ƐŵĞƚŚŽĚĂƉƉůŝĞĚƚŽĐŽƵŶƚƌǇůŝĨĞƚĂďůĞƐĂŶĚĂŐĞ-sex-specific estimates of severity-
adjusted equivalent years of healthy life lost as a fraction of total years lived by each age-sex group.  
The latter is calculated by summing years of healthy life lost due to disability (YLD) across a 
comprehensive set of disease and injury causes drawing on analyses from the Global Burden of 
Disease study (WHO, 2014).  HALE was chosen as the starting point for the analysis as it uses more 
detailed data on morbidity than rival approaches such as disability-free life expectancy, which only 
use binary morbidity data on whether or not a person has disability.  By contrast, HALE uses cardinal 
data on health-related quality of life based on disease prevalence and public views about health loss 
associated with different disease states (Salomon, Wang et al. 2012).  It also has the added benefit 
of being available for a wide range of countries, which is of particular importance when data 
limitations are so prominent.  Again, no disaggregated HALE data is available but the HALE values 
give average measures of population health that take account of both quality and length of life, and 
therefore provide a reasonable starting point. 
 
Stage 2: Adjust HALE according to distribution of life expectancy 
As no life expectancy data that is disaggregated by social characteristics is available, modelled life 
expectancies by wealth quintile (taken from Tranvag, Ali et al. 2013) were used to calculate relative 
weights which were applied to the average HALE values for males (54 HALYs) and females (56 HALYs) 
(WHO, 2015).  The modelled life expectancy values were calculated using a modified logit life table 
system which requires stratified under-5 and adult mortality data. Under-five mortality data by 
gender, urban-rural residence and wealth quintiles from the 2011 EDHS was used.  In 2011 the EDHS 
surveyed 17,817 households 31% in urban areas and 69% in rural areas, interviewing 16,515 women 
and 14,110 men.  Adult mortality rates by the same groups were not available and were, therefore, 
calculated using adult mortality and life expectancy from the Global Burden of Disease study 2010 
and weighted ratios of under-5 mortality rates for the respective groups (see Tranvag, Ali et al. 2013 
for full explanation).  The relative weights were calculated by assuming the modelled life expectancy 
26  CHE Research Paper 135 
 
of the middle wealth quintile, Q3, was equal to the mean life expectancy, and relative weights for 
the other quintile groups were calculated accordingly.  By assuming that the distribution of life 
expectancy applies equally to the morbidity and mortality components of the HALE, these weights 
were applied as relative adjustment factors to the average HALE values to produce a distribution of 
HALE that reflects the distribution of life expectancy among the population according to their 
wealth. 
 
Stage 3: Adjust HALE according to distribution of mortality 
The distribution of HALE obtained in Stage 2 reflects the distribution of life expectancy.  However, a 
second adjustment is required so that it also reflects the distribution of morbidity.  This adjustment 
was based on data on the prevalence of disease disaggregated by wealth quintile group taken from 
the Ethiopia Demographic and Health Survey (Central Statistical Agency and ICF International, 2012). 
Of the available diseases for which prevalence data was available, those selected to form the basis of 
the adjustment were anaemia, diarrhoea and acute respiratory infection (ARI) in children.  This 
selection was based on the diseases that accounted for the largest burden of disease according to 
the Global Burden of Disease study and was restricted to three diseases because of the limited 
number of diseases and health issues for which data is available (GBD, 2010, IHME, 2015).  Only the 
prevalence in children was used because of the limited data on adult morbidity that was available. 
Consequently, for the morbidity adjustment it was assumed that there is equal morbidity in adults as 
in children.  The average morbidity prevalence was calculated from the 3 diseases selected and was 
then subtracted from 100 to equate to the prevalence of good health.  This was then used to 
calculate the relative adjustment factors for quality of life in the same way as for the adjustment for 
the distribution of life expectancy  W assuming that the prevalence of good health for Q3 was equal to 
the average.  By applying these relative adjustment factors to the HALE values obtained in Stage 1, a 
HALE distribution reflecting both the distribution of morbidity and the distribution of life expectancy 
was obtained.  As before, this assumed that the morbidity adjustment applies equally to the 
morbidity and mortality components of HALE. 
 
The Baseline Health Distribution 
Following the adjustments for quality and length of life outlined above, the groups were ordered 
from least to most healthy and adjusted for the size of the group to produce a population 
distribution of HALE at birth (see Figure 1 of main text).  
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Annex Table 1: Modelling the Baseline Health Distribution 
  
Stage 1 Stage 2 Stage 3 
*Average HALE Wealth 
Quintile  
*Modelled 
Life 
expectancy 
Adjustment 
Factor (LE) 
Adjusted HALE 100- 
Average 
Morbidity 
Prevalence 
Adjustment 
Factor (QoL) 
Adjusted HALE 
Female Male Female Male Female Male 
  Q1 53.4 0.88 49.35 47.58 76.5 0.97 48.19 46.47 
  Q2 56.2 0.93 51.93 50.08 78 0.99 51.71 49.87 
56 54 Q3 60.6 1 56 54 78.33 1 56 54 
  Q4 59.9 0.99 55.35 53.38 77.97 0.99 55.09 53.13 
  Q5 62.5 1.03 57.76 55.69 82.97 1.06 61.17 58.99 
*Source: WHO, 2015 
**Source: Tranvag, Ali & Norheim, 2013 
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